Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This promotional webcast series has been developed, organised and funded by Novo Nordisk for UK healthcare professionals only.

Novo Nordisk product information will be discussed.
Prescribing information for OZEMPIC®▼ (semaglutide), RYBELSUS®▼ (semaglutide tablets) & VICTOZA® (liraglutide) and adverse events reporting can be found at the bottom of this page.

Webcast registration

Registration gives you access to all five webcasts at a broadcast time that is convenient for you

Are you a healthcare professional working in primary, community or secondary care?
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk
Click here for OZEMPIC®▼ (semaglutide) Prescribing information
Click here for RYBELSUS®▼ (semaglutide tablets) Prescribing information
Click here for VICTOZA® (liraglutide) Prescribing information

OZEMPIC is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in addition to other medicinal products for the treatment of diabetes.

RYBELSUS is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in combination with other medicinal products for the treatment of diabetes.

VICTOZA is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in addition to other medicinal products for the treatment of diabetes.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.

Job code: UK21OZM00193 | Date of preparation: November 2021

Thank you for registering.

We look forward to welcoming you online. You will receive a confirmation email shortly and we will send you a reminder email closer to the start of the virtual webcast.

You are leaving this site.

You are now leaving https://live.diabetesonthenet.com/staging-register.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.